Back to search

Article

PLXDC1 May Serve As A Target For Combining Antiangiogenic Therapy and Immunotherapy In Gastric Adenocarcinoma

2021-08-24

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold> Based on the immunosuppression of traditional antiangiogenic agents in the treatment of tumors and the newly proposed concept of antiangiogenic therapy combined with immunotherapy, this paper will mainly explore the prospects of PLXDC1 in stomach adenocarcinoma<bold> </bold>(STAD) regarding antiangiogenic therapy and immunotherapy.<bold>Methods</bold> First, th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
27562527-2f51-530d-ae96-7708016e4ba5
DOI
10.21203/rs.3.rs-816727/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PLXDC1 May Serve As A Target For Combining Antiangiogenic Therapy and Immunotherapy In Gastric AdenocarcinomaDOI 10.21203/rs.3.rs-816727/v1
Select a neighboring publication to make it the new centre.